VXB-241 / Vicebio - LARVOL DELTA

A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus. (PubMed, PLoS Pathog) - P1 | "Head-to-head evaluation in mouse immunogenicity studies showed that the VXB-241 candidate vaccine induced a neutralising immune response that was superior or equivalent to the pre-fusion stabilised comparator antigens for either RSV or hMPV, including the RSVPreF3 antigen of the licensed RSV vaccine, Arexvy (GSK). The results presented here have supported progression of VXB-241 into a Phase 1 clinical trial which commenced enrolment in August 2024 (ClinicalTrials.gov ID NCT06556147)."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (clinicaltrials.gov) - P1 | N=144 | Active, not recruiting | Sponsor: Vicebio Australia Proprietary Limited | Trial primary completion date: Aug 2025 ➔ Feb 2025

Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (clinicaltrials.gov) - P1 | N=144 | Active, not recruiting | Sponsor: Vicebio Australia Proprietary Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (clinicaltrials.gov) - P1 | N=136 | Recruiting | Sponsor: Vicebio Australia Proprietary Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (clinicaltrials.gov) - P1 | N=136 | Not yet recruiting | Sponsor: Vicebio Australia Proprietary Limited

New P1 trial • Respiratory Diseases • Respiratory Syncytial Virus Infections